Janssen and Bayer have stopped a phase 3 trial of Xarelto early after results showed it can cut deaths, heart attacks and strokes compared to aspirin. The promising data paves the way for a ...
In the US, Janssen booked sales of $549 million in the last quarter, down almost 19% compared with the same period last year, while outside the US Xarelto generated sales of just over $1bn for Bayer.
The 2026 list price will drop 66% from $13,836 for a 30-day supply to $4,695. Janssen Pharms' Xarelto is prescribed to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback